|Description||Xanomeline is a Muscarinic M1 and M4 receptor agonist under the development of Eli Lilly, though it is also known to act as a M5 receptor antagonist. Xanomeline has been shown to have reasonable efficacy for the treatment of schizophrenia symptoms although gastrointestinal side effects led to a high drop-out rate in clinical trials. Recent studies showed robust improvements in verbal learning and short-term memory associated with xanomeline treatment. In Dec 1998, Phaes-III clinical trials for Alzheimer's disease in USA was discontinued.|
|Synonyms||LY-246708; LY246708; LY 246708; Xanomeline; Memcor; NNC-110232; Hexyloxy-TZTP; HexyloxyTZTP;3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||397ºC at 760 mmHg|
|Current Developer||Eli Lilly|
PF-06767832 is a cell permeable, potent and selective M1 muscarinic acetylcholine receptor Positive Allosteric Modulator (PAM).
Xanomeline is a Muscarinic M1 and M4 receptor agonist under the development of Eli Lilly, though it is also known to act as a M5 receptor antagonist. Xanomeline...
BQCA is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor (mAChR), as it dose-dependently reduces the concentration o...
PD 102807 is a selective mAChR M4 antagonist with IC50 values of 91, 6559, 3441, 95 and 7412 nM for human M4, M1, M2, M3, and M5 receptors respectively.
Methscopolamine is a muscarinic acetylcholine receptor blocker.
Tarafenacin is a highly selective M3 muscarinic receptor antagonist. It was the most potent in inhibiting carbachol-induced bladder contractions of the anti-ch...
Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor...
A muscarinic receptor antagonist. Used in the treatment of urinary incontinence.